Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Open accessThe DOI matches its Crossref record; 475 of the 479 references it cites were found in a registry or an index.
Abstract
There has been an alarming increase in the prevalence of obesity in people with type 1 diabetes in recent years. Although obesity has long been recognized as a major risk factor for the development of type 2 diabetes and a catalyst for complications, much less is known about the role of obesity in the initiation and pathogenesis of type 1 diabetes. Emerging evidence suggests that obesity contributes to insulin resistance, dyslipidemia, and cardiometabolic complications in type 1 diabetes. Unique therapeutic strategies may be required to address these comorbidities within the context of intensive insulin therapy, which promotes weight gain. There is an urgent need for clinical guidelines for the prevention and management of obesity in type 1 diabetes. The development of these recommendations will require a transdisciplinary research strategy addressing metabolism, molecular mechanisms, lifestyle, neuropsychology, and novel therapeutics. In this review, the prevalence, clinical impact, energy balance physiology, and potential mechanisms of obesity in type 1 diabetes are described, with a special focus on the substantial gaps in knowledge in this field. Our goal is to provide a framework for the evidence base needed to develop type 1 diabetes-specific weight management recommendations that account for the competing outcomes of glycemic control and weight management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Self-citationMootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
Research works printed but not linked: 1
- Saudek, 1996, Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial, JAMA, 276, 1322, 10.1001/jama.1996.03540160044031 · DOI · Paper page
Cited by
Items 101–200 of 273
Ahn, M. B., Kim, S.-K., Kim, S. H., Cho, W. K., Suh, J., Cho, K., Suh, B., & Jung, M. H. (2021) · Children · doi:10.3390/children8121155 · Cited by 14
Thong, E. P., Milat, F., Joham, A. E., Mishra, G. D., & Teede, H. J. (2020) · Clinical Endocrinology · doi:10.1111/cen.14281 · Cited by 17
Kaya, D. G., Arslan, N., Ayyıldız, F., Bayramoğlu, E., Turan, H., & Ercan, O. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01593-6 · Cited by 14
Elhabashy, S. A., Abdelhaleem, B. A., Madkour, S. S., Kamal, C. M., & Salah, N. Y. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70041 · Cited by 12
Pregnancy and diabetic ketoacidosis: fetal jeopardy and windows of opportunity
Coetzee, A., Hall, D. R., Langenegger, E. J., van de Vyver, M., & Conradie, M. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1266017 · Cited by 12
“The fi ndings of this study are consistent with recent fi ndings from other studies that indicate that obesity is a highly prevalent problem in individuals with T1D (68 – 71).”
BackgroundResultJiang, Y., Zhang, W., Wei, M., Yin, D., Tang, Y., Jia, W., Wang, C., Guo, J., Li, A., & Gong, Y. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01296-x · Cited by 13
“T1DM is frequently accompanied by disorders of glucose and lipid metabolism and obesity [12, 13].”
BackgroundKostopoulou, E., Kalavrizioti, D., Davoulou, P., Sinopidis, X., Papachristou, E. C., Goumenos, D. S., Dimitriou, G., Spiliotis, B. E., & Papasotiriou, M. (2024) · European Journal of Pediatrics · doi:10.1007/s00431-024-05496-5 · Cited by 12
“Type 1 diabetes mellitus (T1DM) is another chronic disease of precipitously rising prevalence, not only caused by autoimmune destruction of the insulin-producing pancreatic β-cells but also influenced by factors beyond the auto-immune process [5, 6].”
Insulin resistance-associated genetic variants in type 1 diabetes
Miller, R. G., McGurnaghan, S. J., Önengüt-Gümüşcü, S., Chen, W., Colhoun, H. M., Rich, S. S., Orchard, T. J., & Costacou, T. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107842 · Cited by 14
Shah, V. N., Agesen, R. M., Bardtrum, L., Christiansen, E., SNAITH, J. R., & Greenfield, J. R. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305647 · Cited by 11
Podobnik, J., & Prentice, K. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16154 · Cited by 15
Bombaci, B., Calderone, M., Pisa, A. D., Rocca, M. L., Torre, A., Lombardo, F., Salzano, G., & Passanisi, S. (2025) · Medicina · doi:10.3390/medicina61091602 · Cited by 15
“In youth with T1D, obesity and overweight are increasingly recognized as emerging clinical issues, associated with higher cardiometabolic burden and greater insulin resistance [36].”
Amor, A. J., Casas, A., Pané, A., Ruiz, S., Montagud‐Marrahí, E., Andújar, A. M., Ruiz, M., Mayordomo, R., Musquera, M., Ferrer, J., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109026 · Cited by 12
Sperling, M. A., Wolfsdorf, J. I., Menon, R. K., Tamborlane, W. V., Maahs, D. M., Battelino, T., & Phillip, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00021-x · Cited by 13
Self-citationIsmail, H. M., & Evans‐Molina, C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.892291 · Cited by 12
Peczyńska, J., Klonowska, B., Żelazowska‐Rutkowska, B., Polkowska, A., Noiszewska, K., Bossowski, A. T., & Głowińska‐Olszewska, B. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164732 · Cited by 12
“Certain studies have evaluated the impact of obesity and overweight on the development of chronic complications in patients with T1D, suggesting that individuals with obesity are at a higher risk of macrovascular and some microvascular complications [44].”
BackgroundDrawing lines in the sand: The growing threat of obesity in type 1 diabetes
Koufakis, T., Patoulias, D., Zografou, I., Papanas, N., & Popovic, D. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.823 · Cited by 10
Optimizing basal insulin dosing
Lal, R. A., & Maahs, D. M. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.07.030 · Cited by 10
Self-citationHelleputte, S., Stautemas, J., Craemer, M. D., Bogaert, L., Backer, T. L. M. D., Calders, P., & Lapauw, B. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111860 · Cited by 10
Corbin, K. D., IGUDESMAN, D. A., Addala, A., Casu, A., Crandell, J., Kosorok, M. R., Maahs, D. M., Pokaprakarn, T., Pratley, R. E., Souris, K. J., et al. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106765 · Cited by 10
Self-citationThe 13C Glucose Breath Test Accurately Identifies Insulin Resistance in People With Type 1 Diabetes
Mertens, J., Roosens, L., Braspenning, R., Vandebeeck, J., Francque, S., & Block, C. E. M. D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae175 · Cited by 10
Obesity, but not glycemic control, predicts liver steatosis in children with type 1 diabetes
Tas, E., Bai, S., Mak, D., Diaz, E. C., & Dranoff, J. A. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108341 · Cited by 10
Ntavidi, S., Katsanou, P., Marakomichelakis, G., Kasdagli, M., Antiochou, E., Mpali, I., Kakou, A.-M., Tsioufis, K. P., Dimitriadis, G., & Lambadiari, V. (2022) · Nutrients · doi:10.3390/nu15010072 · Cited by 10
“Insulin resistance is also present in T1DM, due, at least in part, to the presence of obesity, chronic hyperglycemia, and the exogenous administration of insulin [49].”
BackgroundChaudhary, R. K., Ali, O., Kumar, A., Kumar, A., & Pervez, A. (2025) · Cureus · doi:10.7759/cureus.80495 · Cited by 11
“Results from studies show that people who have a higher BMI need larger insulin doses because their insulin sensitivity decreases, which leads to complicated treatment, along with elevated metabolic syndrome and cardiovascular risk [14,15].”
Guo, Y., Lin, C., Cai, X., Wu, H., Yan, J., Li, Z., Jiao, R., Bai, S., Yang, W., Lv, F., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112899 · Cited by 9
Functional Foods as Modulators of Epigenetic Mechanisms Affecting Metabolic Health in Adolescence
Kurhaluk, N., Kołodziejska, R., Mazur, Z., Лукаш, О. В., Yakovenko, O., & TKACZENKO, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27042066 · Cited by 12
“Overweight and obesity are becoming increasingly common among young people with T1D, driven by factors such as exogenous insulin therapy, reduced physical activity, fear of hypoglycaemia, and emotional eating [78].”
High Risk of Metabolic Complications Due to High Consumption of Processed Foods
Vellapandian, C., & Singh, A. (2022) · Current Nutrition & Food Science · doi:10.2174/1573401318666220622162038 · Cited by 9
Fang, Y., Liu, W., Cai, X., Zhu, Y., Zhang, M., Gong, S., Wang, X., Lin, C., Zhang, R., Yin, S., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01602-1 · Cited by 9
“For individuals with metabolic syndrome, higher glucose variability often reflected inadequate meal planning and insufficient physical activity [8, 9, 42–47], which were key contributors to the development of metabolic syndrome.”
Ethel Codner, D., Cerda, T., & Gaete, X., V (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.06.002 · Cited by 11
Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood
Kahkoska, A. R., Nguyen, C. T., Jiang, X., Adair, L. S., Agarwal, S., Aiello, A. E., Burger, K. S., Buse, J. B., Dabelea, D., Dolan, L. M., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000886 · Cited by 9
“31 For example, approaches for under or normal weight individuals with elevated HbA1c may be centered on insulin intensification, while approaches for overweight individuals could balance the glycemic benefits of insulin intensification with the potential for weight gain via concurrent behavioral,…”
Self-citationKapelios, C. J., Bonou, M. S., Barmpagianni, A., Tentolouris, A., Tsilingiris, D., Eleftheriadou, I., Skouloudi, M., Kanellopoulos, P. N., Lambadiari, V., Masoura, C., et al. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107913 · Cited by 9
Apperley, L. J., & Ng, S. M. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.11.005 · Cited by 9
Garg, S. K., Aktürk, H. K., Garg, S., Beck, R. W., Bellini, N. J., Bjornstad, P., Carlson, A. L., Carroll, J., Close, K., Block, C., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261449879 · Cited by 8
“31,32 For people with T2D, noninsulin therapeutic options include metformin, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and daily or weekly GLP-1 RAs and more recently, combined GLP-1/GIP dual agonists.”
Kącka, A., Charemska, A., Jarocka‐Cyrta, E., & Głowińska‐Olszewska, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1036109 · Cited by 9
Fridolfsson, C., Thegerström, J., Åkesson, K., Engvall, J. E., & Blomstrand, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-54597-6 · Cited by 9
Lamaro, B. D., Greenfield, J. R., & SNAITH, J. R. (2024) · Journal of Patient Experience · doi:10.1177/23743735241257811 · Cited by 10
TAZ promotes PDX1-mediated insulinogenesis
Jeong, M. G., Kim, H. K., Lee, G., Won, H. Y., Yoon, D. H., & Hwang, E. S. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04216-2 · Cited by 8
“Progressive β-cell loss from autoimmune attack leads to chronic hyperglycemia and increases the prevalence of obesity in type 1 diabetes (T1D); furthermore, obesityinduced hyperglycemia contributes to and exacerbates INS resistance, which is an important clinical feature of type 2 diabetes (T2D) [54, 55].”
BackgroundLee, D. H., Choi, S., Chang, J., Park, Y. J., Kim, J. H., & Park, S. M. (2022) · Endocrine · doi:10.1007/s12020-022-03042-7 · Cited by 8
Elzinga, S. E., Eid, S., McGregor, B. A., Jang, D., Hinder, L. M., Dauch, J. R., Hayes, J. M., Zhang, H., Guo, K., Pennathur, S., et al. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050080 · Cited by 8
“Body weight was higher in db/db T2D versus db/+ STZ T1D mice, consistent with humans; although, increasingly, T1D patients also develop obesity (Corbin et al., 2018).”
IGUDESMAN, D. A., Crandell, J., Zhong, V. W., Sarteau, A. C., Kahkoska, A. R., Corbin, K. D., Pratley, R. E., Kosorok, M. R., Maahs, D. M., & Mayer‐Davis, E. J. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13132 · Cited by 8
Self-citationPastor-Fajardo, M. T., Fajardo-Giménez, M. T., Bosch-Giménez, V. M., & Pastor-Rosado, J. (2022) · BMC Pediatrics · doi:10.1186/s12887-022-03330-1 · Cited by 7
Somolinos-Simón, F. J., García-Sáez, G., Tapia, J. A. R., Corcoy, R., & Hernando, M. E. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111803 · Cited by 7
Is there a role for bariatric surgery in patients with severe obesity and type 1 diabetes?
Dessify, B. J., Wood, G. C., Parker, D. M., Carmichael, D., Petrick, A. T., & Daouadi, M. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.10.013 · Cited by 7
Noninsulin Therapies in Management of Type 1 Diabetes
Saeed, Z. I., Ambalavanan, J., Rayan, M. N., Patadia, P., & Shah, V. N. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.027 · Cited by 7
Thaher, O., Iaroshevych, V., Driouch, J., Hukauf, M., Croner, R. S., & Stroh, C. (2023) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-023-02788-6 · Cited by 6
“A greater risk is posed by the aggravation of existing circulatory or endocrinological disorders or the onset of new diseases with concomitant obesity in this group of patients [14].”
Nicolau, J., Romano, A., Rodríguez, I., Sanchís, P., Puga, M. J., & Masmiquel, L. (2024) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2024.02.007 · Cited by 6
Polycystic ovary syndrome in pediatric obesity and diabetes
DONDI, E., TUFANO, M., VIGONE, M. C., LUCACCIONI, L., POZZOBON, G., Ubertini, G., Mozzillo, E., & Delvecchio, M. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06542-3 · Cited by 8
Bishop, F. K., Addala, A., Corbin, K. D., Muntis, F. R., Pratley, R. E., Riddell, M. C., Mayer‐Davis, E. J., Maahs, D. M., & Zaharieva, D. P. (2023) · Nutrients · doi:10.3390/nu15112500 · Cited by 6
“Overall, there is a pressing need to generate a scientific evidence base to develop weight management guidelines specific to individuals living with T1D [31,68].”
BackgroundSelf-citationRelationship between liver and cardiometabolic health in type 1 diabetes
Tas, E., Vu, B.-M. K., Mendizábal, B., Libman, I. M., & Muzumdar, R. H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1505430 · Cited by 6
Maarouf, O. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-83082-3_6 · Cited by 6
Sarteau, A. C., & Mayer‐Davis, E. J. (2022) · Nutrients · doi:10.3390/nu14040824 · Cited by 9
“, hypertension, dyslipidemia, inflammation, and oxidative stress) [104,105].”
Self-citationThe genetics of a “femaleness/maleness” score in cardiometabolic traits in the UK biobank
Vosberg, D. E., Pausová, Z., & Paus, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-36132-1 · Cited by 6
Tentolouris, A., Koufakis, T., & Fousteris, E. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00693-9 · Cited by 5
“Furthermore, hormonal abnormalities in T1DM, including impaired secretion and/or action of insulin, glucagon, amylin, leptin, and other enteroendocrine hormones, can disrupt appetite regulation and energy homeostasis, thereby impairing the normal control of food intake [43].”
More hypoglycemia not associated with increasing estimated adiposity in youth with type 1 diabetes
Sarteau, A. C., Kahkoska, A. R., Crandell, J., IGUDESMAN, D. A., Corbin, K. D., Kichler, J., Maahs, D. M., Muntis, F. R., Pratley, R. E., Seid, M., et al. (2022) · Pediatric Research · doi:10.1038/s41390-022-02129-1 · Cited by 5
Self-citationPoorani, K., & Karuppasamy, M. (2023) · Cognitive science and technology · doi:10.1007/978-981-99-2742-5_10 · Cited by 5
Change in Body Mass Index in Youth in the First 5 Years After Type 1 Diabetes Mellitus Diagnosis
Ganta, A., Warnick, J. L., Has, P., Gonzalez, M. S., Fredette, M. E., & Topor, L. S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.003 · Cited by 5
Andersen, G., Eloy, R., Heise, T., Gaudier, M., Mégret, C., Seroussi, C., Chan, Y., Soula, O., Riddle, M. C., & DeVries, J. H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15827 · Cited by 5
“18 It has been reported that a large proportion of people with T1D fail to intensify insulin therapy and even reduce or omit injections for fear of weight gain.”
Wu, B., Li, W., Xu, S., Chen, R., Ding, Y., Xu, R., Wu, Z., Bao, M., He, B., & Li, S. (2025) · Medicine · doi:10.1097/md.0000000000042998 · Cited by 6
IGUDESMAN, D. A., Nally, L. M., Grimshaw, A. A., Gunderson, C. G., Considine, E. G., Jacobsen, L. M., Tosur, M., Gottlieb, P. A., Hirsch, I. B., Laffel, L. M., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf448 · Cited by 5
Self-citationSánchez, E., Mizab, C., Sauret, A., Barbé, F., Martí, R., López‐Cano, C., Hernández, M., Gutiérrez-Carrasquilla, L., Carmona, P., González, J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051249 · Cited by 5
“The alarming increase in the prevalence of obesity among patients with type 1 diabetes also favors the negative impact of insulin resistance and low-grade inflammation on the growth and metabolism of bronchoalveolar epithelium and vascular smooth muscle [1,10].”
BackgroundType 1 diabetes, obesity and PCOS: Is type 1 stepping into the shoes of type 2 diabetes?
Ethel Codner, D. (2020) · Clinical Endocrinology · doi:10.1111/cen.14319 · Cited by 5
Vendrame, F., Calhoun, P. M., Bocchino, L. E., Pratley, R. E., & Casu, A. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107884 · Cited by 5
Self-citationLaspe, I., Meier, J. J., & Nauck, M. A. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0322 · Cited by 5
“However, obesity and insulin resistance also occur in T1DM [10,11].”
BackgroundJilani, U. A., OTHMAN, Z. B., & Jilani, S. A. (2022) · Malaysian Journal of Public Health Medicine · doi:10.37268/mjphm/vol.22/no.1/art.1516 · Cited by 5
Complications of obesity in children and youths with type 1 diabetes mellitus
Kącka, A., Charemska, A., Odyjewska, E., Jarocka‐Cyrta, E., & Głowińska‐Olszewska, B. (2025) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2025.152594 · Cited by 4
“In the DCCT/EDIC study, excessive body weight in patients with T1D was reported as a risk factor of dyslipidemia, hypertension, insulin resistance, and extensive atherosclerosis, thus increasing the risk of cardiovascular complications [23, 24].”
Osei, E. P., Ekpor, E., Osei, G. Y., & Akyirem, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01774-7 · Cited by 4
“Obesity has far-reaching clinical implications as it heightens the burden on many organ systems leading to microangiopathic complications [14], poor glycemic con-trol [15], higher risk of insulin resistance, dyslipidemia, and cardiometabolic complications in T1D [7].”
Metabolomic associations of impaired awareness of hypoglycaemia in type 1 diabetes
Varkevisser, R. D. M., Cecil, A., Prehn, C. P., Mul, D., Aanstoot, H., Paterson, A. D., Wolffenbuttel, B. H. R., & van der Klauw, M. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-55032-6 · Cited by 4
Kahkoska, A. R., Crandell, J., Driscoll, K. A., Kichler, J., Seid, M., Mayer‐Davis, E. J., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12805 · Cited by 4
Self-citationKahkoska, A. R., Sarteau, A. C., IGUDESMAN, D. A., Reboussin, B. A., Dabelea, D., Dolan, L. M., Jensen, E. T., Wadwa, R. P., Pihoker, C., & Mayer‐Davis, E. J. (2022) · Journal of Diabetes Research · doi:10.1155/2022/1054042 · Cited by 4
Self-citationDimitriadis, G., & Lambadiari, V. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac704 · Cited by 4
Endocrinology for the Hepatologist
Isaacs, S. D., & Isaacs, A. (2024) · Current Hepatology Reports · doi:10.1007/s11901-024-00639-6 · Cited by 4
Parwez, R., Naeem, M., & Aftab, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95719-9.00002-1 · Cited by 4
Nicolau, J., Romano, A., Rodríguez, I., Sanchís, P., Puga, M. J., & Masmiquel, L. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.02.005 · Cited by 4
Carnero, E. Á., Corbin, K. D., Casu, A., IGUDESMAN, D. A., Bilal, A., Smith, S. R., Kosorok, M. R., Maahs, D. M., Mayer‐Davis, E. J., & Pratley, R. E. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01446-4 · Cited by 4
“The development of obesity in people with T1D is likely to be somewhat different from that in individuals without diabetes due to the need for exogenous insulin delivery (resulting in peripheral over-insulinization and anti-lipolytic effects) and the metabolic effects of hyperglycemia [6].”
Self-citationRyan, L. W. K., Weiying, L., Wright, A., & Tan, L. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009507189 · Cited by 4
Prevalence of obesity in prepubertal and pubertal with Turkish population type 1 diabetes
Özkaya, V., Eren, E., Özkaya, Ş. Ö., & Öngen, Y. D. (2021) · Diabetology International · doi:10.1007/s13340-021-00498-2 · Cited by 4
Bitkin, E. Ç., Kara, C., Yılmaz, G. C., Mammadova, J., & Aydın, H. M. (2021) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2021-0268 · Cited by 4
The effect of exercise on sleep habits of children with type 1 diabetic: a randomized clinical trial
Amiri, N., Karami, K., Valizadeh, F., & Mokhayeri, Y. (2024) · BMC Pediatrics · doi:10.1186/s12887-024-04760-9 · Cited by 5
“In 2021, the global number of people with diabetes is reported to be 8.4 million, and it is predicted to reach 13.5 to 17.4 million by 2040 [2–4].”
BackgroundInfluentialDifferent Types of Physical Activity and Metabolic Control in People With Type 1 Diabetes Mellitus
Štotl, I., Kambič, T., Hadžić, V., & Zdolšek, A. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01210 · Cited by 5
Maqusood, S., Chakole, V., & Dash, S. (2024) · Cureus · doi:10.7759/cureus.60426 · Cited by 3
Patterns of health enhancing physical activity in older patients with diabetes mellitus
Volčanšek, Š., Lunder, M., & Janež, A. (2023) · Science & Sports · doi:10.1016/j.scispo.2022.11.008 · Cited by 3
Epidemiology and Pathogenesis of Type 1 Diabetes
Stene, L. C., & Lernmark, Å. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_2 · Cited by 4
Obesity paradox in individuals with type 1 diabetes
Hamasaki, H. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1670312 · Cited by 3
“Moreover, endocrine alterations such as abnormal glucagon or amylin secretion in the absence of endogenous insulin, together with intensive insulin therapy, have been shown to promote weight gain (24).”
Auch unter Typ-1-Diabetikern verbreitet
Klein, C., & Adamek, H. E. (2021) · Info Diabetologie · doi:10.1007/s15034-020-3640-6 · Cited by 3
“Da auch bei T1D-Patienten eine Zunahme an übergewichtigen Betroffenen beobachtet wird [6], ist auch bei diesem Diabetestyp mit einer Zunahme der Steatosis hepatis zu rechnen.”
BackgroundBone health in young adults with type 1 diabetes and progressive eGFR decline
Babalola, F., Hamilton, J., Zappitelli, M., Elia, Y. T., Curtis, J., Moineddin, R., & Mahmud, F. H. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00169-6 · Cited by 3
“T1D was previously associated with a lean phenotype, however there are recent reports of increasing rates of overweight and obesity in T1D [23].”
BackgroundCorrelates of circulating extracellular vesicle cargo with key clinical features of type 1 diabetesPreprint
Casu, A., López, Y. O. N., Yu, G., Clifford, C., Bilal, A., Petrilli, A. M., Cornnell, H., Corbin, K. D., Iliuk, A. B., Maahs, D. M., et al. (2022) · medRxiv · doi:10.1101/2022.03.10.22272207 · Cited by 3
“The cardiovascular risk should be interpreted in the context of the obesity epidemic that does not spare the T1D population and it is possibly exacerbated by insulin treatment itself (6).”
BackgroundSelf-citationThe Double Whammy of Obesity and Diabetes on Female Reproductive Health
Thong, E. P., & Burden, C. (2020) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1723777 · Cited by 2
Nutritional myths in adolescents and young adults with type 1 diabetes: a pilot study
Kaya, D. G., Arslan, S., Yassıbaş, E., Ayyıldız, F., Bayramoğlu, E., Turan, H., & Evliyaoğlu, O. (2025) · BMC Nutrition · doi:10.1186/s40795-025-01115-0 · Cited by 2
“Obesity exacerbates insulin resistance, high insulin requirements, cardiometabolic risk, and the risk of developing chronic complications in patients with T1DM ( [30, 33]– [34]).”
Kim, K.-J., Kim, S., Oh, R., Cho, S. H., Jang, M., Lee, Y., Kim, G., Jin, S., Hur, K. Y., Kim, J. Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0179 · Cited by 3
Lisco, G., Tullio, A. D., Disoteo, O., Armigliato, M., Guastamacchia, E., Marucci, S., Pergola, G. D., Papini, E., Chianelli, M., Frasoldati, A., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70073 · Cited by 2
“Apart from common risk factors predisposing to weight gain and excess, such as unhealthy eating patterns, lack of physical exercise, or poor sleep quality and quantity, T1D individuals are also exposed to disease‐specific risk factors [5].”
Honda, T., Henry, T. D., VanDerslice, J. A., Porucznik, C. A., Corlin, L., Gilani, O., Kirwa, K., Lázaro-Guevara, J. M., & Pezzolesi, M. G. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112983 · Cited by 2
GLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?
Piras, G., Brasili, S., Demontis, D., Sala, L. D., Cocchiara, F., Maggi, D. C., & Arecco, A. (2026) · Diabetology · doi:10.3390/diabetology7030050 · Cited by 2
Huang, L., Liu, P., Chen, Q., Hu, K., Li, S., Lee, A., Wabitsch, M., Zhu, L. J., Yu, Q., Davis, R. J., et al. (2026) · Science Advances · doi:10.1126/sciadv.aed2780 · Cited by 2
Matson, R. P., Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · Diabetology · doi:10.3390/diabetology7100189
Miętkiewska-Dolecka, M., & Uruska, A. A. (2021) · Journal of Medical Science · doi:10.20883/medical.e531 · Cited by 2
“widely known [19], and are also applicable to the”
BackgroundKaur, K. K. (2019) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000138 · Cited by 2
Krzyżowska, S., Matejko, B., CYRANKA, K. M., Juza, A., Kieć‐Wilk, B., & Klupa, T. (2023) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/161289 · Cited by 2
Mechanisms of Nerve Injury in Diabetes: Dyslipidemia, Bioenergetics, and Oxidative Damage
Eid, S., Noureldein, M. H., Savelieff, M. G., & Feldman, E. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_16 · Cited by 2
Impact of low carbohydrate diet on patients with type 1 Diabetes
Mahmood, B. S. (2023) · E3S Web of Conferences · doi:10.1051/e3sconf/202339101132 · Cited by 2
Boboc, A. A., Ionescu, M.-I., Tătăranu, E., Boboc, C., & Galoş, F. (2024) · Cureus · doi:10.7759/cureus.66456 · Cited by 2
“Conversely, insulin resistance results in elevated insulin needs, which impede glycemic control and weight management [27].”
BackgroundVarkevisser, R. D. M., Sas, T., Aanstoot, H., Wolffenbuttel, B. H. R., & van der Klauw, M. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108893 · Cited by 2
Metadata
- Authors
- Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON)
- Affiliations
- Translational Research Institute for Metabolism and Diabetes (US)
- University of Colorado Denver (US)
- Stanford Medicine (US)
- Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
- Corresponding author
- Corbin, Karen D
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2018-07-27
- Volume
- 39
- Issue
- 5
- Pages
- 629-663
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2884950815
- Cited by
- 262
- References
- 479
- Citations by year
- 2026: 28 · 2025: 35 · 2024: 40 · 2023: 33 · 2022: 43 · 2021: 41 · 2020: 23 · 2019: 14 · 2018: 5
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- North Carolina State University
- Bigfoot Biomedical
- Insulet Corporation
- Orexigen Therapeutics
- Five Prime Therapeutics
- Dexcom
- Zafgen
- NGM Biopharmaceuticals
- York University
- Eisai
- Novo Nordisk
- University of North Carolina at Chapel Hill
- University of Colorado Denver
- Abbott Diabetes Care
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, type 1 diabetes, insulin resistance, dyslipidemia, cardiometabolic complications, intensive insulin therapy, weight gain, energy balance, obesity pathogenesis, weight management, glycemic control, obesity prevalence
- MeSH terms
- Diabetes Mellitus, Type 1, Humans, Insulin Resistance, Life Style, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.